<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39435376</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-7076</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>IJID regions</Title><ISOAbbreviation>IJID Reg</ISOAbbreviation></Journal><ArticleTitle>Predictors and outcomes of patients with COVID-19 admitted to intensive care units in Pakistan and the development of nosocomial fungal infections: Findings and implications.</ArticleTitle><Pagination><StartPage>100445</StartPage><MedlinePgn>100445</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100445</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijregi.2024.100445</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Patients with COVID-19 admitted to intensive care units (ICUs) typically have many complications and co-morbidities, including secondary bacterial and fungal infections, which increase morbidity and mortality. The first step to address this is to measure the prevalence rates, predictors of fungal infections, and outcomes of patients with COVID-19 admitted to ICUs in Pakistan.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Retrospective review of medical records of patients admitted with COVID-19 to the ICUs of six tertiary care hospitals in Pakistan between March 2020 and June 2023.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 636 patients were included; 68.9% were aged ≥50 years and 62.6% were male. Diabetes mellitus was the commonest co-morbidity (23.7%). A total of 67.8% of patients had severe COVID-19, with 23% critical cases. Antibiotics and antipyretics (all patients) were the most frequently prescribed medicines, along with corticosteroids (72.5%). A total of 63 nosocomial fungal infections developed in 53 patients, with mechanical ventilation and tracheal intubation being significant predictors of secondary fungal infections among patients with COVID-19. The mortality rate was 4.9%, with secondary fungal infections significantly associated with higher mortality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Approximately 8% of patients with COVID-19 admitted to the ICUs of tertiary developed secondary fungal infections associated with greater mortality. The key factors associated with secondary fungal infections need to be carefully monitored to reduce future mortality in these patients. We will continue to monitor the situation.</AbstractText><CopyrightInformation>© 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mustafa</LastName><ForeName>Zia Ul</ForeName><Initials>ZU</Initials><AffiliationInfo><Affiliation>Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy Services, District Headquarter (DHQ) Hospital, Pakpattan, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suleman</LastName><ForeName>Aneeqa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Tehsil Head Quarter Hospital, Darya Khan, District Bhakkar, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masood</LastName><ForeName>Muhammad Faiq</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Medicine, Ameer-Ud-Din Medical College, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salman</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nazir</LastName><ForeName>Aftab</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, Niazi Medical and Dental College, Sargodha, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallhi</LastName><ForeName>Tauqeer Hussain</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Yusra Habib</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mudenda</LastName><ForeName>Steward</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, School of Health Sciences, University of Zambia, Lusaka, Zambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Johanna C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South African Vaccination and Immunisation Centre, Sefako Makgatho Health Sciences University, Pretoria, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godman</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seaton</LastName><ForeName>R Andrew</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Queen Elizabeth University Hospital, Glasgow, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scottish Antimicrobial Prescribing Group, Healthcare Improvement Scotland, Glasgow, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>IJID Reg</MedlineTA><NlmUniqueID>9918418183106676</NlmUniqueID><ISSNLinking>2772-7076</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Fungal infections</Keyword><Keyword MajorTopicYN="N">Hospitalization</Keyword><Keyword MajorTopicYN="N">Intensive care units</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Pakistan</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39435376</ArticleId><ArticleId IdType="pmc">PMC11492131</ArticleId><ArticleId IdType="doi">10.1016/j.ijregi.2024.100445</ArticleId><ArticleId IdType="pii">S2772-7076(24)00116-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Levin AT, Owusu-Boaitey N, Pugh S, Fosdick BK, Zwi AB, Malani A, et al. Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. BMJ Glob Health. 2022;7 doi: 10.1136/bmjgh-2022-008477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2022-008477</ArticleId><ArticleId IdType="pmc">PMC9136695</ArticleId><ArticleId IdType="pubmed">35618305</ArticleId></ArticleIdList></Reference><Reference><Citation>Salman M, Mustafa ZU, Khan TM, Shehzadi N, Hussain K. How prepared was Pakistan for the COVID-19 outbreak? Disaster Med Public Health Prep. 2020;14:e44–e45. doi: 10.1017/dmp.2020.247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/dmp.2020.247</ArticleId><ArticleId IdType="pmc">PMC7445450</ArticleId><ArticleId IdType="pubmed">32662386</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhtar H, Afridi M, Akhtar S, Ahmad H, Ali S, Khalid S, et al. Pakistan's response to COVID-19: overcoming national and international hypes to fight the pandemic. JMIR Public Health Surveill. 2021;7:e28517. doi: 10.2196/28517.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/28517</ArticleId><ArticleId IdType="pmc">PMC8136406</ArticleId><ArticleId IdType="pubmed">33877048</ArticleId></ArticleIdList></Reference><Reference><Citation>Worldmeter. Pakistan - coronavirus cases, https://www.worldometers.info/coronavirus/country/pakistan/; 2023 [accessed 20 January 2024].</Citation></Reference><Reference><Citation>Mustafa ZU, Tariq S, Iftikhar Z, Meyer JC, Salman M, Mallhi TH, et al. Predictors and outcomes of healthcare-associated infections among patients with COVID-19 admitted to intensive care units in Punjab, Pakistan; findings and implications. Antibiotics (Basel) 2022;11:1806. doi: 10.3390/antibiotics11121806.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11121806</ArticleId><ArticleId IdType="pmc">PMC9774163</ArticleId><ArticleId IdType="pubmed">36551463</ArticleId></ArticleIdList></Reference><Reference><Citation>Abubakar AR, Sani IH, Godman B, Kumar S, Islam S, Jahan I, et al. Systematic review on the therapeutic options for COVID-19: clinical evidence of drug efficacy and implications. Infect Drug Resist. 2020;13:4673–4695. doi: 10.2147/IDR.S289037.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S289037</ArticleId><ArticleId IdType="pmc">PMC7778508</ArticleId><ArticleId IdType="pubmed">33402839</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborative Group RECOVERY, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshaikh FS, Godman B, Sindi ON, Seaton RA, Kurdi A. Prevalence of bacterial coinfection and patterns of antibiotics prescribing in patients with COVID-19: a systematic review and meta-analysis. PLoS One. 2022;17 doi: 10.1371/journal.pone.0272375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0272375</ArticleId><ArticleId IdType="pmc">PMC9342726</ArticleId><ArticleId IdType="pubmed">35913964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramzan K, Shafiq S, Raees I, Mustafa ZU, Salman M, Khan AH, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalized with COVID-19 during the first five waves of the pandemic in Pakistan; findings and implications. Antibiotics (Basel) 2022;11:789. doi: 10.3390/antibiotics11060789.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11060789</ArticleId><ArticleId IdType="pmc">PMC9219883</ArticleId><ArticleId IdType="pubmed">35740195</ArticleId></ArticleIdList></Reference><Reference><Citation>Gul B, Sana M, Saleem A, Mustafa ZU, Salman M, Khan YH, et al. Antimicrobial dispensing practices during COVID-19 and the implications for Pakistan. Antibiotics (Basel) 2023;12:1018. doi: 10.3390/antibiotics12061018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12061018</ArticleId><ArticleId IdType="pmc">PMC10294926</ArticleId><ArticleId IdType="pubmed">37370337</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Azzam Lopez A, Diez-Remesal Y, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis. 2021;40:495–502. doi: 10.1007/s10096-020-04142-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-020-04142-w</ArticleId><ArticleId IdType="pmc">PMC7778834</ArticleId><ArticleId IdType="pubmed">33389263</ArticleId></ArticleIdList></Reference><Reference><Citation>Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive fungal infections complicating COVID-19: a narrative review. J Fungi (Basel) 2021;7:921. doi: 10.3390/jof7110921.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jof7110921</ArticleId><ArticleId IdType="pmc">PMC8620819</ArticleId><ArticleId IdType="pubmed">34829210</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslove DM, Sibley S, Boyd JG, Goligher EC, Munshi L, Bogoch II, et al. Complications of critical COVID-19: diagnostic and therapeutic considerations for the mechanically ventilated patient. Chest. 2022;161:989–998. doi: 10.1016/j.chest.2021.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.10.011</ArticleId><ArticleId IdType="pmc">PMC8511547</ArticleId><ArticleId IdType="pubmed">34655568</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshrefy AJ, Alwohaibi RN, Alhazzaa SA, Almaimoni RA, AlMusailet LI, AlQahtani SY, et al. Incidence of bacterial and fungal secondary infections in COVID-19 patients admitted to the ICU. Int J Gen Med. 2022;15:7475–7485. doi: 10.2147/IJGM.S382687.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S382687</ArticleId><ArticleId IdType="pmc">PMC9518678</ArticleId><ArticleId IdType="pubmed">36187162</ArticleId></ArticleIdList></Reference><Reference><Citation>Coşkun AS, Durmaz ŞÖ. Fungal infections in COVID-19 intensive care patients. Pol J Microbiol. 2021;70:395–400. doi: 10.33073/pjm-2021-039.</Citation><ArticleIdList><ArticleId IdType="doi">10.33073/pjm-2021-039</ArticleId><ArticleId IdType="pmc">PMC8459001</ArticleId><ArticleId IdType="pubmed">34584533</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira HC, Bezerra BT, Rodrigues ML. Antifungal development and the urgency of minimizing the impact of fungal diseases on public health. ACS Bio Med Chem Au. 2023;3:137–146. doi: 10.1021/acsbiomedchemau.2c00055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsbiomedchemau.2c00055</ArticleId><ArticleId IdType="pmc">PMC10125384</ArticleId><ArticleId IdType="pubmed">37101810</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20:557–571. doi: 10.1038/s41579-022-00720-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00720-1</ArticleId><ArticleId IdType="pmc">PMC8962932</ArticleId><ArticleId IdType="pubmed">35352028</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustafa ZU, Khan AH, Salman M, Syed Sulaiman SA, Godman B. Antimicrobial utilization among neonates and children: a multicenter point prevalence study from Leading Children's Hospitals in Punjab. Pakistan. Antibiotics (Basel) 2022;11:1056. doi: 10.3390/antibiotics11081056.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11081056</ArticleId><ArticleId IdType="pmc">PMC9405424</ArticleId><ArticleId IdType="pubmed">36009925</ArticleId></ArticleIdList></Reference><Reference><Citation>Swenson KE, Swenson ER. Pathophysiology of acute respiratory distress syndrome and COVID-19 lung injury. Crit Care Clin. 2021;37:749–776. doi: 10.1016/j.ccc.2021.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccc.2021.05.003</ArticleId><ArticleId IdType="pmc">PMC8162817</ArticleId><ArticleId IdType="pubmed">34548132</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KH, Lee SH. COVID-19 and fungal diseases. Antibiotics (Basel) 2022;11:803. doi: 10.3390/antibiotics11060803.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11060803</ArticleId><ArticleId IdType="pmc">PMC9219667</ArticleId><ArticleId IdType="pubmed">35740209</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafat Z, Ramandi A, Khaki PA, Ansari S, Ghaderkhani S, Haidar H, et al. Fungal and bacterial co-infections of the respiratory tract among patients with COVID-19 hospitalized in intensive care units. Gene Rep. 2022;27 doi: 10.1016/j.genrep.2022.101588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genrep.2022.101588</ArticleId><ArticleId IdType="pmc">PMC8902060</ArticleId><ArticleId IdType="pubmed">35281669</ArticleId></ArticleIdList></Reference><Reference><Citation>Varshini M, Ganesan V, Charles J. Secondary bacterial and fungal infections in COVID-19 patients. Int J Antimicrob Agents. 2021;58</Citation></Reference><Reference><Citation>Soltani S, Zandi M, Faramarzi S, Shahbahrami R, Vali M, Rezayat SA, et al. Worldwide prevalence of fungal coinfections among COVID-19 patients: a comprehensive systematic review and meta-analysis. Osong Public Health Res Perspect. 2022;13:15–23. doi: 10.24171/j.phrp.2021.0293.</Citation><ArticleIdList><ArticleId IdType="doi">10.24171/j.phrp.2021.0293</ArticleId><ArticleId IdType="pmc">PMC8907610</ArticleId><ArticleId IdType="pubmed">35255675</ArticleId></ArticleIdList></Reference><Reference><Citation>Adzic-Vukicevic T, Mladenovic M, Jovanovic S, Soldatović I. Radovanovic-Spurnic A. Invasive fungal disease in COVID-19 patients: a single-center prospective observational study. Front Med (Lausanne) 2023;10 doi: 10.3389/fmed.2023.1084666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1084666</ArticleId><ArticleId IdType="pmc">PMC10288186</ArticleId><ArticleId IdType="pubmed">37359005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3:e543–e552. doi: 10.1016/S2666-5247(21)00237-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00237-8</ArticleId><ArticleId IdType="pmc">PMC8789240</ArticleId><ArticleId IdType="pubmed">35098179</ArticleId></ArticleIdList></Reference><Reference><Citation>Maini R, Saini N, Bhavana K, Bharti B, Walia S, Kori N, et al. Clinico-epidemiologic characteristics of patients reported in the mycotic infections in COVID-19 registry. Am J Trop Med Hyg. 2023;108:584–587. doi: 10.4269/ajtmh.22-0503.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.22-0503</ArticleId><ArticleId IdType="pmc">PMC9978542</ArticleId><ArticleId IdType="pubmed">36535246</ArticleId></ArticleIdList></Reference><Reference><Citation>Negm EM, Mohamed MS, Rabie RA, Fouad WS, Beniamen A, Mosallem A, et al. Fungal infection profile in critically ill COVID-19 patients: a prospective study at a large teaching hospital in a middle-income country. BMC Infect Dis. 2023;23:246. doi: 10.1186/s12879-023-08226-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08226-8</ArticleId><ArticleId IdType="pmc">PMC10111294</ArticleId><ArticleId IdType="pubmed">37072718</ArticleId></ArticleIdList></Reference><Reference><Citation>AK Ak, Gupta V. StatPearls Publishing LLC; Treasure Island: 2023. Rhino-orbital cerebral mucormycosis.</Citation><ArticleIdList><ArticleId IdType="pubmed">32491361</ArticleId></ArticleIdList></Reference><Reference><Citation>Irfan A, Kamran AH, Ammar M, Rahman SU. Frequency and survival of Covid associated mucormycosis patients at tertiary care hospitals in Pakistan: a retrospective observational study. Health Sci Rep. 2023;6:e1083. doi: 10.1002/hsr2.1083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hsr2.1083</ArticleId><ArticleId IdType="pmc">PMC9896361</ArticleId><ArticleId IdType="pubmed">36761033</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangneux JP, Dannaoui E, Fekkar A, Luyt CE, Botterel F, De Prost N, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2022;10:180–190. doi: 10.1016/S2213-2600(21)00442-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00442-2</ArticleId><ArticleId IdType="pmc">PMC8626095</ArticleId><ArticleId IdType="pubmed">34843666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>